Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

15.03 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,545
Open 15.03
Bid (Size) 15.00 (1,600)
Ask (Size) 15.20 (100)
Prev. Close 15.03
Today's Range 15.03 - 15.03
52wk Range 12.73 - 39.89
Shares Outstanding 70,814,462
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-36.3%
-36.3%
1 Month
-40.4%
-40.4%
3 Month
-53.6%
-53.6%
6 Month
-29.8%
-29.8%
1 Year
-50.0%
-50.0%

More News

Read More
News headline image
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
From Pomerantz LLP
Via GlobeNewswire
Ultragenyx (NASDAQ:RARE) Q2 Beats Estimates, Reaffirms Guidance as Shares Rise ↗
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
From Pomerantz LLP
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Thursday's session: top gainers and losers ↗
Via Chartmill
Gapping stocks in Thursday's session ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy ↗
Via MarketBeat
News headline image
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx (RARE) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Ultragenyx Pharmaceutical Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Ultragenyx Pharmaceutical Inc. - Common Stock publicly traded?
Yes, Ultragenyx Pharmaceutical Inc. - Common Stock is publicly traded.
What exchange does Ultragenyx Pharmaceutical Inc. - Common Stock trade on?
Ultragenyx Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock?
The ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock is RARE on the Nasdaq Stock Market
What is the current price of Ultragenyx Pharmaceutical Inc. - Common Stock?
The current price of Ultragenyx Pharmaceutical Inc. - Common Stock is 15.03
When was Ultragenyx Pharmaceutical Inc. - Common Stock last traded?
The last trade of Ultragenyx Pharmaceutical Inc. - Common Stock was at 09/30/26 04:00 PM ET
What is the market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock?
The market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock is 1.06B
How many shares of Ultragenyx Pharmaceutical Inc. - Common Stock are outstanding?
Ultragenyx Pharmaceutical Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.